CY1115444T1 - Ανταγωνιστικα αντισωματα il-17 - Google Patents

Ανταγωνιστικα αντισωματα il-17

Info

Publication number
CY1115444T1
CY1115444T1 CY20141100628T CY141100628T CY1115444T1 CY 1115444 T1 CY1115444 T1 CY 1115444T1 CY 20141100628 T CY20141100628 T CY 20141100628T CY 141100628 T CY141100628 T CY 141100628T CY 1115444 T1 CY1115444 T1 CY 1115444T1
Authority
CY
Cyprus
Prior art keywords
competitive antibodies
antibody
human
disease
heavy
Prior art date
Application number
CY20141100628T
Other languages
English (en)
Inventor
Padova Franco E Di
Hermann Gram
Hans Hofstetter
Margit Jeschke
Jean-Michel Rondeau
Den Berg Wim Van
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115444(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1115444T1 publication Critical patent/CY1115444T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Παρέχεται ένα μόριο πρόσδεσης IL-17, συγκεκριμένα ένα αντίσωμα στην ανθρώπινη IL-17, κατά προτίμηση ένα ανθρώπινο αντίσωμα στην IL-17, όπου οι υπερμεταβλητές περιοχές των βαριών και των ελαφριών αλυσίδων έχουν ακολουθίες αμινοξέος όπως ορίστηκαν, για χρήση στη θεραπεία μιας νόσου ή διαταραχής που προκαλείται από την ΙL-17, π.χ. ρευματοειδή αρθρίτιδα.
CY20141100628T 2004-08-05 2014-08-08 Ανταγωνιστικα αντισωματα il-17 CY1115444T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417487.6A GB0417487D0 (en) 2004-08-05 2004-08-05 Organic compound
EP10175150.1A EP2364729B3 (en) 2004-08-05 2005-08-04 IL-17 antagonistic antibodies

Publications (1)

Publication Number Publication Date
CY1115444T1 true CY1115444T1 (el) 2017-01-04

Family

ID=32982602

Family Applications (6)

Application Number Title Priority Date Filing Date
CY20111100936T CY1111963T1 (el) 2004-08-05 2011-09-27 Ανταγωνιστικα αντισωματα il-17
CY20141100628T CY1115444T1 (el) 2004-08-05 2014-08-08 Ανταγωνιστικα αντισωματα il-17
CY20151100401T CY1116256T1 (el) 2004-08-05 2015-05-07 Il-17 ανταγωνιστικα αντισωματα
CY2015030C CY2015030I2 (el) 2004-08-05 2015-07-10 Ανταγωνιστικα αντισωματα il-17
CY181100727T CY1120723T1 (el) 2004-08-05 2018-07-11 Ανταγωνιστικα αντισωματα il-17
CY2018027C CY2018027I1 (el) 2004-08-05 2018-10-10 Ανταγωνιστικα αντισωματα il-17

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20111100936T CY1111963T1 (el) 2004-08-05 2011-09-27 Ανταγωνιστικα αντισωματα il-17

Family Applications After (4)

Application Number Title Priority Date Filing Date
CY20151100401T CY1116256T1 (el) 2004-08-05 2015-05-07 Il-17 ανταγωνιστικα αντισωματα
CY2015030C CY2015030I2 (el) 2004-08-05 2015-07-10 Ανταγωνιστικα αντισωματα il-17
CY181100727T CY1120723T1 (el) 2004-08-05 2018-07-11 Ανταγωνιστικα αντισωματα il-17
CY2018027C CY2018027I1 (el) 2004-08-05 2018-10-10 Ανταγωνιστικα αντισωματα il-17

Country Status (39)

Country Link
US (8) US7807155B2 (el)
EP (5) EP1776142B9 (el)
JP (1) JP4682200B2 (el)
KR (2) KR20080029018A (el)
CN (1) CN101001645B (el)
AR (1) AR050200A1 (el)
AT (1) ATE517924T1 (el)
AU (2) AU2005268857C1 (el)
BR (3) BR122018075556B1 (el)
CA (1) CA2573586C (el)
CY (6) CY1111963T1 (el)
DK (4) DK2902039T3 (el)
EC (1) ECSP077198A (el)
ES (4) ES2677245T3 (el)
FR (1) FR15C0048I2 (el)
GB (1) GB0417487D0 (el)
HK (3) HK1101277A1 (el)
HR (3) HRP20110758T4 (el)
HU (4) HUE025815T2 (el)
IL (1) IL180717A (el)
LT (3) LT2902039T (el)
LU (2) LU92768I2 (el)
MA (1) MA28982B1 (el)
MX (1) MX2007001338A (el)
MY (1) MY144925A (el)
NL (1) NL300749I2 (el)
NO (9) NO336279B1 (el)
NZ (1) NZ552658A (el)
PE (1) PE20060418A1 (el)
PL (4) PL1776142T4 (el)
PT (4) PT1776142E (el)
RU (2) RU2426741C3 (el)
SG (1) SG155186A1 (el)
SI (4) SI1776142T1 (el)
TN (1) TNSN07034A1 (el)
TR (1) TR201808057T4 (el)
TW (1) TWI359153B (el)
WO (1) WO2006013107A1 (el)
ZA (1) ZA200700242B (el)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
NZ595262A (en) 2005-09-01 2013-03-28 Us Gov Health & Human Serv Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease
CN101326195B9 (zh) 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
DK2532681T3 (en) 2005-12-20 2015-01-05 Sbi Biotech Co Ltd Anti-ILT7 antibody
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
KR20080099290A (ko) * 2006-01-31 2008-11-12 노파르티스 아게 암 치료용 ｉｌ-17 길항 항체
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
CA2655372A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
CN101646690B (zh) 2006-08-11 2013-10-23 默沙东公司 抗il-17a抗体
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
MX2009009167A (es) 2007-02-28 2009-09-04 Schering Corp Terapia de combinacion para el tratamiento de trastornos inmunes.
KR20160017119A (ko) 2007-05-29 2016-02-15 노파르티스 아게 항-ｉｌ-1-베타 치료법에 대한 신규 적응증
CA2690568A1 (en) * 2007-06-20 2008-12-24 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
WO2009015063A2 (en) * 2007-07-23 2009-01-29 Centocor Methods and compositions for treating fibrosis related disorders using il-17 antagonists
US20110195509A1 (en) * 2007-09-06 2011-08-11 Drew Pardoll Treatment of th17-mediated autoimmune disease via inhibition of stat 3
WO2009072802A2 (en) * 2007-12-03 2009-06-11 Amorepacific Corporation Composition for slimming
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
AU2009204441B2 (en) * 2008-01-09 2015-03-05 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
KR20110014607A (ko) 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
EA024654B1 (ru) * 2008-04-29 2016-10-31 Эмджен Рисерч (Мьюник) Гмбх Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии
CA2721713C (en) 2008-05-05 2019-07-09 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
MX2010013239A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY31861A (es) 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
AU2009296299A1 (en) 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human IL 17 and uses thereof
NZ611324A (en) 2009-03-05 2015-02-27 Abbvie Inc Il-17 binding proteins
ES2655877T3 (es) * 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
MX2011011729A (es) 2009-05-05 2012-04-10 Novimmune Sa Anticuerpo anti il-17f y metodos de uso de los mismos.
UY32870A (es) 2009-09-01 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20130064788A1 (en) * 2009-10-10 2013-03-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
RU2012119756A (ru) 2009-10-15 2013-11-20 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011053763A2 (en) 2009-10-30 2011-05-05 Centocor Ortho Biotech Inc. Il-17a antagonists
US9932403B2 (en) 2010-05-20 2018-04-03 Ablynx Nv Biological materials related to HER3
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN103154026B (zh) * 2010-08-05 2016-07-06 安奈普泰斯生物有限公司 抗il-17的抗体
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
WO2012045082A2 (en) 2010-10-01 2012-04-05 Jason Schrum Engineered nucleic acids and methods of use thereof
EP4137514A1 (en) * 2010-10-08 2023-02-22 Novartis AG Methods of treating psoriasis using il-17 antagonists
JP2014503482A (ja) * 2010-11-05 2014-02-13 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法
AU2014259523B2 (en) * 2010-11-05 2016-02-04 Novartis Ag Methods of treating psoriatic arthritis using IL-17 antagonists
TW201307845A (zh) 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
JP5947041B2 (ja) * 2011-01-07 2016-07-06 第一三共ヘルスケア株式会社 安全なｉｌ−１７産生抑制剤
EP2663869A1 (en) * 2011-01-13 2013-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cardiovascular event in a subject
MX341489B (es) 2011-01-14 2016-08-23 Ucb Pharma Sa Moleculas de anticuerpo que se unen a interleucina 17a (il-17a) e interleucina 17f (il-17f).
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
SG193545A1 (en) 2011-03-29 2013-11-29 Glaxosmithkline Llc Buffer system for protein purification
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (en) 2011-10-03 2021-12-01 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2013077907A1 (en) 2011-11-21 2013-05-30 Novartis Ag Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
WO2013087912A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
DK2791160T3 (da) 2011-12-16 2022-05-30 Modernatx Inc Modificerede mrna-sammensætninger
MX2014008101A (es) 2011-12-30 2014-09-25 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17.
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
BR112014024903A2 (pt) 2012-04-05 2017-07-11 Hoffmann La Roche anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos
AR090738A1 (es) 2012-04-20 2014-12-03 Novartis Ag Metodos para el tratamiento de espondilitis anquilosante usando antagonistas de il-17
TWI609882B (zh) 2012-05-22 2018-01-01 必治妥美雅史谷比公司 雙特異性抗體及其使用方法
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
TW201811825A (zh) 2012-11-01 2018-04-01 美商艾伯維有限公司 抗-ｖｅｇｆ／ｄｌｌ４雙重可變區域免疫球蛋白及其用途
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
MA38322B1 (fr) 2013-02-08 2018-09-28 Novartis Ag Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires
TW201512219A (zh) 2013-03-15 2015-04-01 Abbvie Inc 針對ＩＬ－１β及／或ＩＬ－１７之雙特異性結合蛋白
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
JP6255099B2 (ja) 2013-08-15 2017-12-27 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
EP3039039B1 (en) 2013-08-30 2021-03-10 Takeda GmbH Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2929662C (en) 2013-11-18 2023-05-02 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-17a binding agent and uses thereof
EP3101035B1 (en) * 2014-01-28 2021-10-06 Beijing Hanmi Pharmaceutical Co., Ltd. Bifunctional fusion protein, preparation method therefor, and use thereof
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
CN115944734A (zh) 2014-09-10 2023-04-11 诺华股份有限公司 使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
PL3245224T3 (pl) 2015-01-12 2021-01-25 Affibody Ab Polipeptydy wiążące il-17a
WO2016123329A2 (en) 2015-01-28 2016-08-04 Genentech, Inc. Gene expression markers and treatment of multiple sclerosis
CN108251431B (zh) * 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3322725A1 (en) 2015-07-16 2018-05-23 Eli Lilly and Company Treatment of pruritus
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
AU2016342578A1 (en) 2015-10-19 2018-03-29 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (IL-17) antagonists
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
CN114874322A (zh) 2016-03-10 2022-08-09 维埃拉生物股份有限公司 Ilt7结合分子及其使用方法
CN109153713B (zh) 2016-03-10 2022-12-27 艾科赛扬制药股份有限公司 活化素2型受体结合蛋白及其用途
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
FR3051673B1 (fr) * 2016-05-24 2018-06-22 Assistance Publique - Hopitaux De Paris Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
JP2019521156A (ja) 2016-07-19 2019-07-25 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
US11072651B2 (en) 2016-09-14 2021-07-27 Beijing Hanmi Pharm. Co., Ltd. Antibody specifically binding to IL-17A, encoding nucleic acid, and method of using the antibody
JP2019505516A (ja) 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
US10738131B2 (en) 2017-02-10 2020-08-11 Genentech, Inc. Anti-tryptase antibodies, compositions thereof, and uses thereof
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
US10676522B2 (en) 2017-05-05 2020-06-09 Novartis Ag Methods of selectively treating asthma using IL-17 antagonists
CN108359011B (zh) 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
KR20200083996A (ko) 2017-11-02 2020-07-09 노파르티스 아게 인터류킨-17(il-17)을 사용하여 건병증을 치료하는 방법
US20200277369A1 (en) * 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
EP3717907A1 (en) 2017-11-30 2020-10-07 Novartis AG Bcma-targeting chimeric antigen receptor, and uses thereof
WO2019191563A1 (en) * 2018-03-29 2019-10-03 Remd Biotherapeutics, Inc. Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
WO2020024931A1 (en) * 2018-07-31 2020-02-06 Shen Weiqun Anti-il-17a antibodies and use thereof
EP3856772A1 (en) 2018-09-25 2021-08-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
US20220127350A1 (en) 2019-01-31 2022-04-28 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
AU2020284114A1 (en) * 2019-05-31 2022-01-20 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
WO2021018035A1 (zh) 2019-07-26 2021-02-04 神州细胞工程有限公司 人源化抗il17a抗体及其应用
EP4006053A4 (en) 2019-07-30 2022-10-26 Jiangsu Hengrui Medicine Co., Ltd. METHOD OF TREATMENT OF AUTOIMMUNE DISEASE BY IL-17 ANTAGONISTS
CA3155108A1 (en) 2019-09-20 2021-03-25 Novartis Ag Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists
TW202126330A (zh) * 2019-09-25 2021-07-16 國立大學法人東京大學 全身性硬化症治療用醫藥組合物
JP2022549464A (ja) 2019-09-30 2022-11-25 ヤンセン ファーマシューティカ エヌ．ベー． 大分子モジュレータを用いたｉｌ－１７標的結合アッセイのための組成物及び方法
AR121183A1 (es) 2019-11-19 2022-04-27 Novartis Ag Métodos de tratamiento de la nefritis lúpica con antagonistas de interleucina-17 (il-17)
IL293354A (en) 2019-12-06 2022-07-01 Novartis Ag Methods for treating flatulence using interleukin-17 (il-17) antagonists
CN114805577B (zh) * 2019-12-31 2023-11-21 南京融捷康生物科技有限公司 针对il-17ra蛋白的抗体及其制备方法和应用
IL298882A (en) 2020-06-23 2023-02-01 Novartis Ag Methods for treating thyroid eye disease and Graves' orbitopathy using interleukin-17 (IL-17) antagonists
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
CA3199095A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
US20240043523A1 (en) 2020-12-02 2024-02-08 Fresenius Kabi Deutschland Gmbh Methods of selectively reducing antibodies
JP2023554489A (ja) 2020-12-22 2023-12-27 ノバルティス アーゲー 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法
WO2023209519A1 (en) 2022-04-25 2023-11-02 Novartis Ag Crystalline forms of an il-17 inhibitor
WO2023223211A1 (en) 2022-05-16 2023-11-23 Novartis Ag Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
WO2023223263A1 (en) 2022-05-18 2023-11-23 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
EP4406553A1 (en) * 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
WO2024156841A1 (en) * 2023-01-27 2024-08-02 Fresenius Kabi Deutschland Gmbh Biopharmaceutical composition
CN117843778B (zh) * 2023-12-21 2024-07-26 北京贝来药业有限公司 针对白介素家族成员的新型纳米抗体及其产品和应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
KR100467998B1 (ko) 1995-03-23 2005-11-25 임뮤넥스 코포레이션 Il-17수용체
CA2227220A1 (en) 1995-07-19 1997-02-06 Genetics Institute, Inc. Human ctla-8 and uses of ctla-8-related proteins
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
AU7439996A (en) 1995-10-27 1997-05-15 Institut National De La Sante Et De La Recherche Medicale Novel uses of mammalian ctla-8 and related reagents
ES2326347T3 (es) 1996-11-27 2009-10-07 Immunex Corporation Metodo para regular la produccion de oxido nitrico.
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
ES2333385T3 (es) 1997-09-17 2010-02-19 Human Genome Sciences, Inc. Proteina del tipo de interleuquina-17.
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
EP1044022B1 (en) 1997-11-10 2006-03-15 Cytimmune Sciences, Inc. Compositions and methods for targeted delivery of factors
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
WO1999032632A1 (en) 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
JP2003502006A (ja) 1998-01-09 2003-01-21 イミュネックス・コーポレーション Ｉｌ−１７ｒｈｄｎａ及びポリペプチド
WO1999035267A1 (en) 1998-01-09 1999-07-15 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
EP1056842A2 (en) 1998-02-11 2000-12-06 Maxygen, Inc. Genetic vaccine vector engineering
NZ508878A (en) 1998-05-15 2003-08-29 Genentech Inc IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
ES2300154T3 (es) 1998-09-17 2008-06-01 Zymogenetics, Inc. Factor de crecimiento de transformacion beta-9 en mamiferos (ztgfss9).
WO2000020593A1 (en) 1998-10-02 2000-04-13 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
JP2000186046A (ja) * 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
AU1071200A (en) 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
DE29820466U1 (de) 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
NZ511991A (en) 1999-01-11 2004-03-26 Schering Corp Interleukin-17 related mammalian cytokines. Polynucleotides encoding them. uses
AR022237A1 (es) 1999-01-11 2002-09-04 Schering Corp Citoquinas mamiferas purificadas; reactivos y metodos relacionados
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
CN1192796C (zh) 1999-02-12 2005-03-16 斯克里普斯研究学院 联合应用抗血管生成和免疫治疗以治疗肿瘤和转移的方法
US6036128A (en) 1999-05-17 2000-03-14 Common Ground Recycling, Inc. Tire shredding machine and method of using the same
EP1053751A1 (en) * 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
AU6677000A (en) 1999-08-27 2001-03-26 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
JP2001086046A (ja) * 1999-09-09 2001-03-30 Nec Corp カメラ付き携帯電話装置
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU2001296229A1 (en) 2000-10-13 2002-04-29 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease
AU2002246746B2 (en) * 2000-10-18 2007-05-31 Kirin-Amgen, Inc. Methods for treating rheumatoid arthritis using il-17 antagonists
CA2435151A1 (en) 2001-01-25 2002-12-27 Zymogenetics, Inc. Method for treating psoriasis
DK1391464T3 (da) * 2001-04-27 2008-01-14 Kirin Pharma Kk Anti-CD40 monoklonalt antistof
CA2467521A1 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
AU2003259995B2 (en) 2002-08-28 2009-07-02 Immunex Corporation Compositions and methods for treating cardiovascular disease
AU2004270103B2 (en) * 2003-05-21 2012-02-23 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies against Bacillusanthracis protective antigen
ATE395083T1 (de) 2003-11-21 2008-05-15 Ucb Pharma Sa Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität
EP1761643A1 (en) * 2004-05-03 2007-03-14 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
NZ595262A (en) 2005-09-01 2013-03-28 Us Gov Health & Human Serv Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease

Also Published As

Publication number Publication date
CA2573586C (en) 2013-06-25
US20140079719A1 (en) 2014-03-20
SG155186A1 (en) 2009-09-30
SI2366405T1 (sl) 2015-07-31
HUE025815T2 (en) 2016-04-28
IL180717A0 (en) 2007-06-03
DK1776142T3 (da) 2011-10-31
DK2366405T3 (en) 2015-05-11
EP2364729B3 (en) 2015-06-24
CY2015030I2 (el) 2017-11-14
BR122018075556B1 (pt) 2022-10-18
IL180717A (en) 2012-07-31
SI2902039T1 (en) 2018-07-31
SI2364729T1 (sl) 2014-08-29
MX2007001338A (es) 2008-03-11
NO2018007I1 (no) 2018-02-14
ECSP077198A (es) 2007-02-28
CY1116256T1 (el) 2017-02-08
LUC00088I2 (el) 2018-12-17
PE20060418A1 (es) 2006-06-15
LT2902039T (lt) 2018-06-25
DK2364729T6 (en) 2015-07-06
US8119131B2 (en) 2012-02-21
ZA200700242B (en) 2008-08-27
NO348010B1 (no) 2024-06-17
AU2010201689A1 (en) 2010-05-20
EP1776142B1 (en) 2011-07-27
RU2011113153A (ru) 2012-10-20
ES2677245T3 (es) 2018-07-31
NO20171697A1 (no) 2007-03-30
JP2008507988A (ja) 2008-03-21
BRPI0513078A (pt) 2008-04-22
PL2364729T3 (pl) 2014-10-31
TWI359153B (en) 2012-03-01
HK1207559A1 (en) 2016-02-05
AU2005268857B8 (en) 2010-05-27
ES2536228T3 (es) 2015-05-21
NO20150065L (no) 2007-03-30
HUS1500037I1 (hu) 2017-10-30
TW200617025A (en) 2006-06-01
GB0417487D0 (en) 2004-09-08
LU92768I2 (fr) 2015-11-03
PL1776142T3 (pl) 2011-12-30
PL2902039T3 (pl) 2018-09-28
CN101001645A (zh) 2007-07-18
HRP20110758T1 (en) 2011-11-30
US20100215666A1 (en) 2010-08-26
CY2015030I1 (el) 2015-11-04
US20150152178A1 (en) 2015-06-04
US9765140B2 (en) 2017-09-19
AR050200A1 (es) 2006-10-04
NO2022026I1 (no) 2022-06-24
RU2007108067A (ru) 2008-09-10
AU2005268857C1 (en) 2012-01-19
RU2426741C3 (ru) 2017-11-15
KR100852523B1 (ko) 2008-08-14
ES2367440T9 (es) 2021-04-28
FR15C0048I1 (fr) 2015-08-28
CY2018027I2 (el) 2020-05-29
US20190270804A1 (en) 2019-09-05
PT1776142E (pt) 2011-10-06
KR20080029018A (ko) 2008-04-02
EP3409288A1 (en) 2018-12-05
MY144925A (en) 2011-11-30
NO341384B1 (no) 2017-10-30
MA28982B1 (fr) 2007-11-01
ES2367440T7 (es) 2015-07-14
ES2367440T3 (es) 2011-11-03
HRP20110758T4 (hr) 2015-07-31
NO2015023I2 (no) 2015-10-26
EP2902039A1 (en) 2015-08-05
EP1776142B3 (en) 2015-06-24
US20120107325A1 (en) 2012-05-03
HRP20181069T1 (hr) 2018-09-07
HK1101277A1 (en) 2007-10-12
EP2366405B1 (en) 2015-02-25
KR20070036166A (ko) 2007-04-02
PT2366405E (pt) 2015-06-30
US20170355762A1 (en) 2017-12-14
TNSN07034A1 (en) 2008-06-02
EP2366405A2 (en) 2011-09-21
NO2016017I1 (no) 2016-08-23
NO337129B1 (no) 2016-01-25
RU2426741C2 (ru) 2011-08-20
NO336279B1 (no) 2015-07-06
CY2018027I1 (el) 2020-05-29
LTC1776142I2 (lt) 2022-07-11
AU2005268857B2 (en) 2010-01-28
LTPA2015029I1 (lt) 2022-07-11
BRPI0513078B8 (pt) 2019-08-27
NL300749I2 (nl) 2017-11-02
FR15C0048I2 (fr) 2015-11-20
NO20151787L (no) 2006-02-06
PT2364729E (pt) 2014-09-01
AU2005268857A1 (en) 2006-02-09
US7807155B2 (en) 2010-10-05
HUE038187T2 (hu) 2018-10-29
EP2364729B1 (en) 2014-05-14
HUS1800040I1 (hu) 2018-11-28
ES2487533T3 (es) 2014-08-21
ES2487533T7 (es) 2015-07-14
WO2006013107A1 (en) 2006-02-09
US8617552B2 (en) 2013-12-31
US20230235038A1 (en) 2023-07-27
CA2573586A1 (en) 2006-02-09
PL2366405T3 (pl) 2015-08-31
HK1256639A1 (zh) 2019-09-27
AU2010201689B2 (en) 2011-09-29
ATE517924T1 (de) 2011-08-15
CN101001645B (zh) 2012-09-05
EP2902039B1 (en) 2018-04-11
PT2902039T (pt) 2018-07-17
CY1120723T1 (el) 2019-12-11
BRPI0513078B1 (pt) 2019-02-19
US10344084B2 (en) 2019-07-09
PL1776142T4 (pl) 2018-04-30
BRPI0513078C1 (pt) 2021-05-25
NO2015023I1 (no) 2015-11-02
EP2364729A2 (en) 2011-09-14
DK2364729T3 (da) 2014-07-21
PL2364729T6 (pl) 2016-06-30
CY1111963T1 (el) 2015-11-04
NO20150064L (no) 2007-03-30
HRP20150480T1 (hr) 2015-07-17
NO20070985L (no) 2007-03-30
EP2366405A3 (en) 2012-01-18
LTPA2018515I1 (lt) 2018-10-25
SI1776142T1 (sl) 2011-11-30
NZ552658A (en) 2009-11-27
BR122017009404B1 (pt) 2022-02-22
TR201808057T4 (tr) 2018-06-21
EP1776142B9 (en) 2016-09-07
PL1776142T6 (pl) 2016-06-30
JP4682200B2 (ja) 2011-05-11
DK2902039T3 (en) 2018-07-16
US20090280131A1 (en) 2009-11-12
NO337286B1 (no) 2016-02-29
EP1776142A1 (en) 2007-04-25
EP2364729A3 (en) 2012-01-18
DK1776142T6 (en) 2015-07-06

Similar Documents

Publication Publication Date Title
CY1120723T1 (el) Ανταγωνιστικα αντισωματα il-17
CY1107989T1 (el) Ανασυνδυασμενα αντισωματα της ανθρωπινης ιντepλευκινης-1 βητα
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
EA201070888A1 (ru) Антитела и их производные
CY1108779T1 (el) Αντισωματα για την ανθρωπινη il-1 βητα
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
DK1734995T3 (da) Monoklonale antistoffer og hepatocyytvækstfaktor
PE20110797A1 (es) Anticuerpos anti mn
RS53318B (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
DK1699826T3 (da) Syntetiske immunoglobulindomæner med bindende egenskaber konstrueret i regioner af molekylet forskellig fra de komplementaritets-bestemmende domæner
CY1110134T1 (el) Αντισωματα ειδικα για το cd22 και η θεραπευτικη και διαγνωστικη χρηση τους
EA200700876A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
NZ594682A (en) Fully human antibodies specific to cadm1
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
RU2011142183A (ru) Средство для лечения ревматоидного артрита
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
ATE478707T1 (de) Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen
EA200701031A1 (ru) Молекулы, способствующие гематопоэзу
UA108734C2 (uk) Моноклональне антитіло, що специфічно зв'язується з протеїнконвертазою субтілізин кексин типу 9 (pcsk9)
CY1115000T1 (el) Ανθρωπινα αντισωματα εναντια στη λυσσα και χρησεις αυτων
EA202190387A1 (ru) Антитело к cd38 человека и его применение
TH114402B (th) แอนติบอดีของ il-17 แอนติโกนิสติก